Search Results for: Alzheimer

3183 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
MMP3 and SPP1 matrix metallopeptidase 3 (stromelysin 1, progelatinase) secreted phosphoprotein 1
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Signaling by PDGF
  • Integrin cell surface interactions
  • Degradation of the extracellular matrix
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and SPOCK3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and CCL7 matrix metallopeptidase 3 (stromelysin 1, progelatinase) chemokine (C-C motif) ligand 7
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • Peptide ligand-binding receptors
  • Chemokine receptors bind chemokines
  • Class A/1 (Rhodopsin-like receptors)
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and BCAN matrix metallopeptidase 3 (stromelysin 1, progelatinase) brevican
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • MPS IIIB - Sanfilippo syndrome B
  • Diseases of glycosylation
  • Heparan sulfate/heparin (HS-GAG) metabolism
  • Defective B4GALT7 causes EDS, progeroid type
  • MPS I - Hurler syndrome
  • MPS IX - Natowicz syndrome
  • Chondroitin sulfate/dermatan sulfate metabolism
  • CS/DS degradation
  • Defective SLC26A2 causes chondrodysplasias
  • Glycosaminoglycan metabolism
  • Degradation of the extracellular matrix
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
  • Defective CHST14 causes EDS, musculocontractural type
  • Defective PAPSS2 causes SEMD-PA
  • MPS IIIA - Sanfilippo syndrome A
  • Myoclonic epilepsy of Lafora
  • ECM proteoglycans
  • Defective CHST6 causes MCDC1
  • Glycogen storage diseases
  • MPS IIID - Sanfilippo syndrome D
  • A tetrasaccharide linker sequence is required for GAG synthesis
  • Chondroitin sulfate biosynthesis
  • MPS IIIC - Sanfilippo syndrome C
  • Diseases associated with glycosaminoglycan metabolism
  • Mucopolysaccharidoses
  • Defective EXT2 causes exostoses 2
  • MPS II - Hunter syndrome
  • Defective B3GAT3 causes JDSSDHD
  • Defective CHST3 causes SEDCJD
  • Defective EXT1 causes exostoses 1, TRPS2 and CHDS
  • MPS IV - Morquio syndrome A
  • Dermatan sulfate biosynthesis
  • MPS IV - Morquio syndrome B
  • Defective CHSY1 causes TPBS
  • MPS VII - Sly syndrome
  • Metabolism of carbohydrates
  • MPS VI - Maroteaux-Lamy syndrome
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and CCL13 matrix metallopeptidase 3 (stromelysin 1, progelatinase) chemokine (C-C motif) ligand 13
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and TNFSF11 matrix metallopeptidase 3 (stromelysin 1, progelatinase) tumor necrosis factor (ligand) superfamily, member 11
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
PDE4D and APP phosphodiesterase 4D, cAMP-specific amyloid beta (A4) precursor protein
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Opioid Signalling
  • DARPP-32 events
  • Signaling by GPCR
  • Platelet degranulation
  • Metabolic disorders of biological oxidation enzymes
  • RIP-mediated NFkB activation via ZBP1
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • Amyloids
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Peptide ligand-binding receptors
  • Toll Like Receptor 5 (TLR5) Cascade
  • The NLRP3 inflammasome
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Response to elevated platelet cytosolic Ca2+
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • G alpha (i) signalling events
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • G alpha (q) signalling events
  • Class A/1 (Rhodopsin-like receptors)
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • ZBP1(DAI) mediated induction of type I IFNs
  • ECM proteoglycans
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Advanced glycosylation endproduct receptor signaling
  • Innate Immune System
  • Inflammasomes
  • Cytosolic sensors of pathogen-associated DNA
  • MyD88-independent cascade
  • GPCR ligand binding
  • Toll-Like Receptors Cascades
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • TRAF6 mediated NF-kB activation
  • Adenosine monophosphate
  • Dyphylline
  • Ketotifen
  • Iloprost
  • Roflumilast
  • Piclamilast
  • 4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]-2-Pyrrolidinone
  • 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol
  • 6-(4-Difluoromethoxy-3-Methoxy-Phenyl)-2h-Pyridazin-3-One
  • 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • (S)-Rolipram
  • Cis-4-Cyano-4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]Cyclohexanecarboxylic Acid
  • (R)-Rolipram
  • 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • Ibudilast
  • (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one
  • 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
  • 3-ISOBUTYL-1-METHYLXANTHINE
  • 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
PIM1 and APP Pim-1 proto-oncogene, serine/threonine kinase amyloid beta (A4) precursor protein
  • Signaling by GPCR
  • Platelet degranulation
  • Metabolic disorders of biological oxidation enzymes
  • RIP-mediated NFkB activation via ZBP1
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • Amyloids
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Peptide ligand-binding receptors
  • Toll Like Receptor 5 (TLR5) Cascade
  • The NLRP3 inflammasome
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Response to elevated platelet cytosolic Ca2+
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • G alpha (i) signalling events
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • G alpha (q) signalling events
  • Class A/1 (Rhodopsin-like receptors)
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • ZBP1(DAI) mediated induction of type I IFNs
  • ECM proteoglycans
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Advanced glycosylation endproduct receptor signaling
  • Innate Immune System
  • Inflammasomes
  • Cytosolic sensors of pathogen-associated DNA
  • MyD88-independent cascade
  • GPCR ligand binding
  • Toll-Like Receptors Cascades
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • TRAF6 mediated NF-kB activation
  • Adenosine monophosphate
  • 3,4-Dihydroxy-1-Methylquinolin-2(1h)-One
  • Staurosporine
  • 2-(4-Morpholinyl)-8-Phenyl-4h-1-Benzopyran-4-One
  • (3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One
  • Rbt205 Inhibitor
  • Quercetin
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Phosphonoserine
  • S,S-(2-Hydroxyethyl)Thiocysteine
  • IMIDAZOPYRIDAZIN 1
  • 4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one
  • (4R)-7,8-dichloro-1\',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4\'-piperidine]-4-carbonitrile
  • N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine
  • (2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile
  • (4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4\'-piperidine]-4-carbonitrile
  • 5,7-DIHYDROXY-2-(3,4,5-TRIHYDROXYPHENYL)-4H-CHROMEN-4-ONE
  • 6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE
  • 4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine
  • N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine
  • 2,3-diphenyl-1H-indole-7-carboxylic acid
GSK3B and PIK3R1 glycogen synthase kinase 3 beta phosphoinositide-3-kinase, regulatory subunit 1 (alpha)
  • Signaling by the B Cell Receptor (BCR)
  • Hedgehog 'off' state
  • Signaling by FGFR in disease
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • CRMPs in Sema3A signaling
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • APC truncation mutants have impaired AXIN binding
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Regulation of HSF1-mediated heat shock response
  • Cellular response to heat stress
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • TCF dependent signaling in response to WNT
  • Signaling by Hedgehog
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Metabolism of lipids and lipoproteins
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Interleukin receptor SHC signaling
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by FGFR1 mutants
  • Interleukin-7 signaling
  • Role of phospholipids in phagocytosis
  • Phospholipid metabolism
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • PI3K Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • G-protein beta:gamma signalling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • G alpha (q) signalling events
  • Signaling by ERBB2
  • Signaling by EGFR
  • GPCR downstream signaling
  • Signaling by Interleukins
  • TCR signaling
  • Signaling by VEGF
  • GP1b-IX-V activation signalling
  • Downstream signal transduction
  • Signaling by FGFR mutants
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Nephrin interactions
  • Interleukin-2 signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • G alpha (q) signalling events
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • IRS-mediated signalling
  • PIP3 activates AKT signaling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • Synthesis of PIPs at the plasma membrane
  • IRS-related events triggered by IGF1R
  • G beta:gamma signalling through PI3Kgamma
  • PI3K events in ERBB2 signaling
  • Regulation of signaling by CBL
  • Downstream signaling of activated FGFR
  • G alpha (12/13) signalling events
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • PI Metabolism
  • Innate Immune System
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • IRS-mediated signalling
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • GPVI-mediated activation cascade
  • Interleukin receptor SHC signaling
  • Signaling by FGFR1 fusion mutants
  • Constitutive Signaling by EGFRvIII
  • PI3K Cascade
  • Lithium
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • I-5
  • N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • Adenosine-5\'-Diphosphate
  • (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • Isoproterenol
  • (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
GSK3B and APP glycogen synthase kinase 3 beta amyloid beta (A4) precursor protein
  • Signaling by the B Cell Receptor (BCR)
  • Hedgehog 'off' state
  • Signaling by FGFR in disease
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • CRMPs in Sema3A signaling
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • APC truncation mutants have impaired AXIN binding
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Regulation of HSF1-mediated heat shock response
  • Cellular response to heat stress
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • TCF dependent signaling in response to WNT
  • Signaling by Hedgehog
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Signaling by GPCR
  • Platelet degranulation
  • Metabolic disorders of biological oxidation enzymes
  • RIP-mediated NFkB activation via ZBP1
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • Amyloids
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Peptide ligand-binding receptors
  • Toll Like Receptor 5 (TLR5) Cascade
  • The NLRP3 inflammasome
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Response to elevated platelet cytosolic Ca2+
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • G alpha (i) signalling events
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • G alpha (q) signalling events
  • Class A/1 (Rhodopsin-like receptors)
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • ZBP1(DAI) mediated induction of type I IFNs
  • ECM proteoglycans
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Advanced glycosylation endproduct receptor signaling
  • Innate Immune System
  • Inflammasomes
  • Cytosolic sensors of pathogen-associated DNA
  • MyD88-independent cascade
  • GPCR ligand binding
  • Toll-Like Receptors Cascades
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • TRAF6 mediated NF-kB activation
  • Lithium
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • I-5
  • N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • Adenosine-5\'-Diphosphate
  • (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
GSK3B and BCL3 glycogen synthase kinase 3 beta B-cell CLL/lymphoma 3
  • Signaling by the B Cell Receptor (BCR)
  • Hedgehog 'off' state
  • Signaling by FGFR in disease
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • CRMPs in Sema3A signaling
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • APC truncation mutants have impaired AXIN binding
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Regulation of HSF1-mediated heat shock response
  • Cellular response to heat stress
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • TCF dependent signaling in response to WNT
  • Signaling by Hedgehog
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Lithium
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • I-5
  • N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • Adenosine-5\'-Diphosphate
  • (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
CHRNA4 and VSNL1 cholinergic receptor, nicotinic, alpha 4 (neuronal) visinin-like 1
  • Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
  • Acetylcholine Binding And Downstream Events
  • Postsynaptic nicotinic acetylcholine receptors
  • Activation of Nicotinic Acetylcholine Receptors
  • Presynaptic nicotinic acetylcholine receptors
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Highly sodium permeable acetylcholine nicotinic receptors
  • Highly calcium permeable nicotinic acetylcholine receptors
  • Transmission across Chemical Synapses
  • Nicotine
  • Butabarbital
  • Butalbital
  • Talbutal
  • Pentobarbital
  • Secobarbital
  • Metharbital
  • Thiopental
  • Galantamine
  • Primidone
  • Methylphenobarbital
  • Phenobarbital
  • Varenicline
  • Amobarbital
  • Aprobarbital
  • Butethal
  • Heptabarbital
  • Hexobarbital
  • Barbital
  • Barbituric acid derivative
GSK3B and PSEN1 glycogen synthase kinase 3 beta presenilin 1
  • Signaling by the B Cell Receptor (BCR)
  • Hedgehog 'off' state
  • Signaling by FGFR in disease
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • CRMPs in Sema3A signaling
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • APC truncation mutants have impaired AXIN binding
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Regulation of HSF1-mediated heat shock response
  • Cellular response to heat stress
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • TCF dependent signaling in response to WNT
  • Signaling by Hedgehog
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Degradation of the extracellular matrix
  • Lithium
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • I-5
  • N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • Adenosine-5\'-Diphosphate
  • (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
GSK3B and BZW2 glycogen synthase kinase 3 beta basic leucine zipper and W2 domains 2
  • Signaling by the B Cell Receptor (BCR)
  • Hedgehog 'off' state
  • Signaling by FGFR in disease
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • CRMPs in Sema3A signaling
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • APC truncation mutants have impaired AXIN binding
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Regulation of HSF1-mediated heat shock response
  • Cellular response to heat stress
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • TCF dependent signaling in response to WNT
  • Signaling by Hedgehog
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Lithium
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • I-5
  • N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • Adenosine-5\'-Diphosphate
  • (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
DRD5 and NCS1 dopamine receptor D5 neuronal calcium sensor 1
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Class A/1 (Rhodopsin-like receptors)
  • Amine ligand-binding receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Dopamine receptors
  • Ziprasidone
  • Cabergoline
  • Ropinirole
  • Olanzapine
  • Pramipexole
  • Lisuride
  • Apomorphine
  • Fenoldopam
  • Dopamine
  • Carphenazine
  • Pergolide
  • Bromocriptine
  • Quetiapine
  • Levodopa
  • Aripiprazole
  • Methotrimeprazine
  • Zuclopenthixol
  • Rotigotine
MAPK10 and APP mitogen-activated protein kinase 10 amyloid beta (A4) precursor protein
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • FCERI mediated MAPK activation
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Innate Immune System
  • TRIF-mediated TLR3/TLR4 signaling
  • MAP kinase activation in TLR cascade
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Oxidative Stress Induced Senescence
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Signaling by GPCR
  • Platelet degranulation
  • Metabolic disorders of biological oxidation enzymes
  • RIP-mediated NFkB activation via ZBP1
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • Amyloids
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Peptide ligand-binding receptors
  • Toll Like Receptor 5 (TLR5) Cascade
  • The NLRP3 inflammasome
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Response to elevated platelet cytosolic Ca2+
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • G alpha (i) signalling events
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • G alpha (q) signalling events
  • Class A/1 (Rhodopsin-like receptors)
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • ZBP1(DAI) mediated induction of type I IFNs
  • ECM proteoglycans
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Advanced glycosylation endproduct receptor signaling
  • Innate Immune System
  • Inflammasomes
  • Cytosolic sensors of pathogen-associated DNA
  • MyD88-independent cascade
  • GPCR ligand binding
  • Toll-Like Receptors Cascades
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • TRAF6 mediated NF-kB activation
  • 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
  • Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine
  • Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine
  • 9-(4-Hydroxyphenyl)-2,7-Phenanthroline
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide
  • 4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide
  • (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime
  • (3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime
  • (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime
  • 5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide
  • N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine
  • N-{2\'-[(4-FLUOROPHENYL)AMINO]-4,4\'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE
  • 2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide
  • 1-(3-BROMOPHENYL)-7-CHLORO-6-METHOXY-3,4-DIHYDROISOQUINOLINE
METAP2 and APP methionyl aminopeptidase 2 amyloid beta (A4) precursor protein
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Visual phototransduction
  • The phototransduction cascade
  • Diseases associated with visual transduction
  • Signaling by GPCR
  • Platelet degranulation
  • Metabolic disorders of biological oxidation enzymes
  • RIP-mediated NFkB activation via ZBP1
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • Amyloids
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Peptide ligand-binding receptors
  • Toll Like Receptor 5 (TLR5) Cascade
  • The NLRP3 inflammasome
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Response to elevated platelet cytosolic Ca2+
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • G alpha (i) signalling events
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • G alpha (q) signalling events
  • Class A/1 (Rhodopsin-like receptors)
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • ZBP1(DAI) mediated induction of type I IFNs
  • ECM proteoglycans
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Advanced glycosylation endproduct receptor signaling
  • Innate Immune System
  • Inflammasomes
  • Cytosolic sensors of pathogen-associated DNA
  • MyD88-independent cascade
  • GPCR ligand binding
  • Toll-Like Receptors Cascades
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • TRAF6 mediated NF-kB activation
  • L-Methionine
  • 3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium
  • Fumagillin
  • D-Methionine
  • N\'-(2s,3r)-3-Amino-4-Cyclohexyl-2-Hydroxy-Butano-N-(4-Methylphenyl)Hydrazide
  • (E)-(2r,3r,4s,5r)-3,4,5-Trihydroxy-2-Methoxy-8,8-Dimethyl-Non-6-Enoic Acid ((3s,6r)-6-Hydroxy-2-Oxo-Azepan-3-Yl)-Amide
  • 2-Methyl-2-Propanol
  • (2s,3r)-3-Amino-2-Hydroxy-5-(Ethylsulfanyl)Pentanoyl-((S)-(-)-(1-Naphthyl)Ethyl)Amide
  • Ovalicin
  • 5-BROMO-2-{[(4-CHLOROPHENYL)SULFONYL]AMINO}BENZOIC ACID
  • 5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID
  • 2-[(PHENYLSULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID
  • 2-[({2-[(1Z)-3-(DIMETHYLAMINO)PROP-1-ENYL]-4-FLUOROPHENYL}SULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID
  • N\'-((2S,3R)-3-AMINO-2-HYDROXY-5-(ISOPROPYLSULFANYL)PENTANOYL)-N-3-CHLOROBENZOYL HYDRAZIDE
  • 3-ETHYL-6-{[(4-FLUOROPHENYL)SULFONYL]AMINO}-2-METHYLBENZOIC ACID
  • (CHLOROACETYL)CARBAMIC ACID (3R,4S,5S,5R)-5-METHOXY-4-[(2R,3R)-2-METHYL-3-(3-METHYL-2-BUTENYL)OXIRANYL]-1-OXASPIRO[2.5]OCT-6-YL ESTER
MMP12 and PLAUR matrix metallopeptidase 12 (macrophage elastase) plasminogen activator, urokinase receptor
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Post-translational protein modification
  • Attachment of GPI anchor to uPAR
  • Dissolution of Fibrin Clot
  • Post-translational modification: synthesis of GPI-anchored proteins
  • Acetohydroxamic Acid
  • Marimastat
  • CP-271485
  • PF-00356231
  • Batimastat
  • 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4\'-Ethoxy-1,1\'-Biphenyl-4-Yl)-4-Oxobutanoic Acid
  • (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE
  • N-(biphenyl-4-ylsulfonyl)-D-leucine
  • N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE
  • N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine
  • N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide
  • 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide
  • N-oxo-2-(phenylsulfonylamino)ethanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[(4-methoxyphenyl)sulfonyl]-D-alanine
  • Alteplase
  • Urokinase
  • Reteplase
  • Anistreplase
  • Tenecteplase
MMP12 and TFPI matrix metallopeptidase 12 (macrophage elastase) tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Extrinsic Pathway
  • Formation of Fibrin Clot (Clotting Cascade)
  • Acetohydroxamic Acid
  • Marimastat
  • CP-271485
  • PF-00356231
  • Batimastat
  • 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4\'-Ethoxy-1,1\'-Biphenyl-4-Yl)-4-Oxobutanoic Acid
  • (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE
  • N-(biphenyl-4-ylsulfonyl)-D-leucine
  • N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE
  • N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine
  • N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide
  • 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide
  • N-oxo-2-(phenylsulfonylamino)ethanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[(4-methoxyphenyl)sulfonyl]-D-alanine
  • Coagulation factor VIIa
  • Dalteparin
MMP12 and LPA matrix metallopeptidase 12 (macrophage elastase) lipoprotein, Lp(a)
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Acetohydroxamic Acid
  • Marimastat
  • CP-271485
  • PF-00356231
  • Batimastat
  • 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4\'-Ethoxy-1,1\'-Biphenyl-4-Yl)-4-Oxobutanoic Acid
  • (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE
  • N-(biphenyl-4-ylsulfonyl)-D-leucine
  • N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE
  • N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine
  • N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide
  • 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide
  • N-oxo-2-(phenylsulfonylamino)ethanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[(4-methoxyphenyl)sulfonyl]-D-alanine
  • Aminocaproic Acid

Page 3 out of 160 pages